Practice Expertise
- Corporate Compliance
- Direct Investment
- Life Sciences and Healthcare
- Mergers and Acquisitions
Areas of Practice
- Corporate Compliance
- Direct Investment
- Life Sciences and Healthcare
- Mergers and Acquisitions
Profile
Mr. Gu practiced law with Covington & Burling LLP in Shanghai, Washington, D.C., and New York for approximately 8 years before joining Han Kun Law Offices in 2022. Prior to Covington, Mr. Gu also interned and worked for many years in the New York office of Jun He Law Offices and the Shanghai office of Advokatfirman Vinge KB.
Mr. Gu focuses on corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical, and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, and drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities.
Specifically, Mr. Gu covers a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has co-authored the China chapter of Editions 7, 8, 9, and 10 (2019-2022) of "The Life Sciences Law Review" and the Chambers Life Sciences Global Practice Guide (2022).
Mr. Gu focuses on corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical, and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, and drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities.
Specifically, Mr. Gu covers a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has co-authored the China chapter of Editions 7, 8, 9, and 10 (2019-2022) of "The Life Sciences Law Review" and the Chambers Life Sciences Global Practice Guide (2022).
Bar Admissions
PRC Bar Qualification
Member of the New York State Bar
Education
Mr. Gu received a Bachelor of Laws and a Bachelor of Economics from East China University of Political Science and Law and Shanghai University of International Business and Economics, respectively. He also received an LL.M. degree from NYU School of Law.
Areas of Practice
- Corporate Compliance
- Direct Investment
- Life Sciences and Healthcare
- Mergers and Acquisitions
Articles
Key Takeaways from China's Pilot Plan for Segmented Production of Biological Products
By Yang (Aaron) Gu, Pengfei YOU, Duzhiyun ZHENG, Matt ZHANG, Franky YU, Leyi WANG, Shuwen SUN |October 2024China Pilots Lifting Restrictions on Foreign Investment in Stem Cell, Gene Therapy, and Genetic Diagnosis Sectors in Four Free Trade Zones
By Yang (Aaron) Gu, Pengfei YOU, Duzhiyun ZHENG, Matt ZHANG, Franky YU, Leyi WANG, Shuwen SUN |September 2024China Released Draft Medical Device Law for Comments
By Yang (Aaron) Gu, Pengfei YOU, Duzhiyun ZHENG, Matt ZHANG, Franky YU, Leyi WANG, Shuwen SUN |September 2024
Meet our Firms and Professionals
WSG’s member firms include legal, investment banking and accounting experts across industries and on a global scale. We invite you to meet our member firms and professionals.
